Clinton to drugmakers: Explain your prices; New amicus briefs for Amarin against FDA;

> Former President Bill Clinton had some advice for drugmakers at the BIO meeting Monday: He urged the industry to "explain, explain, explain" the reasons why Americans pay so much more for drugs than other health systems do. Report

> Sanofi ($SNY) won European approval to market Gardasil 9, the new version of the human papillomavirus vaccine the French drugmaker markets along with Merck & Co ($MRK). Report

> Amicus briefs are piling up in Amarin's ($AMRN) lawsuit against the FDA, which claims its off-label marketing plans should be covered by the First Amendment. Report

> Growth in Africa's pharma market makes the continent the only place where genuinely high growth is still achievable, McKinsey analysts say; they predict sales there will climb toward $65 billion by 2020 from $20.8 billion in 2013. Report

And Finally... FitBit's fitness trackers face threats on all sides, but the company can learn some lessons from BlackBerry's ($BBRY) travails. Report

Suggested Articles

In a head-to-head against Bayer's Nexavar, Opdivo failed to significantly extend patients' lives in newly diagnosed liver cancer patients.

Lions Health shared what worked, what campaigns they wish they had created and what they’ll take back home to talk about with their colleagues.

AMAG's female libido drug Vyleesi has just won FDA approval. But will it reach blockbuster state? Management and analysts have different opinions.